CONSTITUENT REPORT
citral
Citral is the classic lemon-smelling aldehydic constituent shared across lemongrass, litsea, lemon myrtle, and other citral-rich oils in the AromaForge archive. Chemically it is not a single stereoisomer but a commercial and natural mixture dominated by the geometric isomers geranial and neral. The evidence base is stronger for identity, fragrance safety, antimicrobial research, and preclinical inflammation models than for human wellness outcomes, so the safest archive framing is that citral is a high-impact lemon odorant with meaningful in-vitro and animal research plus well-established skin-sensitization review history.
Chemical identity and composition
PubChem classifies citral as C10H16O with IUPAC name (2E)-3,7-dimethylocta-2,6-dienal and notes that commercial citral is a mixture. In fragrance and essential-oil practice, citral usually refers to the combined geranial-plus-neral fraction rather than one isolated isomer.
Aroma and practical use
- Use the recorded strong lemon, citrusy, aldehydic, fresh, sharp, citrus descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2020 J Nat Prod mouse study reported that oral citral at 50-300 mg/kg significantly inhibited carrageenan-induced paw edema and thermal allodynia and also modulated LPS- and zymosan-linked inflammatory models.
This is one of the stronger constituent-level anti-inflammatory papers because it tested multiple inflammatory triggers and included pathway-interference experiments rather than relying on a single edema model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 PubMed-listed study on acute lung injury reported that citral inhibited lipopolysaccharide-induced acute lung injury and investigated molecular mechanisms in that model.
This supports the broader preclinical pattern that citral is studied as an inflammation-modulating aldehyde, but it is still animal evidence rather than consumer-use evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 review concluded that citral has documented antibacterial, antifungal, antibiofilm, antiparasitic, antiproliferative, anti-inflammatory, and antioxidant research signals and can reduce microbial load in food matrices.
This is useful for SEO and archive context because it consolidates the antimicrobial literature while clearly remaining secondary evidence rather than a direct clinical claim.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2008 regulatory toxicology paper identified a human no observed effect level for induction of dermal sensitization to citral at 1400 microg/cm2 based on a weight-of-evidence review.
This is one of the clearest primary safety takeaways for citral and helps explain why archive safety language should center sensitization rather than phototoxicity.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedCitral has a well-developed fragrance-allergen literature, and accessible primary safety papers focus mainly on induction of dermal sensitization rather than on phototoxicity.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The latest public European SCCS final opinion dated 26 August 2024 says citral can be considered safe for induction of sensitisation at the proposed cosmetic use concentrations under QRA2, while also stating that the methodology still needs refinement before a firm overall safety conclusion is drawn.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Positive efficacy-style claims for citral are still mostly based on in-vitro and animal models, so archive wording should avoid implying established human therapeutic benefit.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Eugenol report →CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvacrol report →citronellalAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read citronellal report →CuminaldehydeAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Cuminaldehyde report →(E)-cinnamaldehydeAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read (E)-cinnamaldehyde report →LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Limonene report →GeraniolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Geraniol report →alpha-TerpineolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read alpha-Terpineol report →How the effects were investigated
tlr4_tlr2_dectin1_and_cb2_linked_inflammation_modulation
A mouse J Nat Prod study reported that citral reduced edema and hyperalgesia triggered by carrageenan, LPS, and zymosan, with pathway experiments implicating TLR4, TLR2/dectin-1, CB2 receptor signaling, and ATP-sensitive potassium channels.
This experimental finding does not establish benefit, dose or safety in people using this blend.
membrane_active_antimicrobial_aldehyde_behavior
A 2023 antimicrobial review summarizes citral's preclinical activity as involving direct effects on microbial viability and load reduction across food and pharmaceutical models, consistent with a reactive aldehydic constituent used for preservation-oriented applications.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify strong constituent-specific human clinical efficacy evidence for isolated citral.
- Most accessible mechanistic and benefit-oriented sources remain preclinical or review-based.
- Because many essential-oil datasets split citral into geranial and neral, occurrence is often archived under the separate isomers rather than under a combined citral line item.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.